US Broker Ratings

CRISPR Therapeutics AG (CRSP) Investor Outlook: Navigating a 12.15% Potential Upside in Gene Editing Innovations

CRISPR Therapeutics AG (NASDAQ: CRSP) stands at the forefront of the biotechnology sector, offering investors a compelling opportunity to engage with groundbreaking gene-editing technologies. With a current market capitalization of..

CG Oncology, Inc. (CGON) Stock Analysis: A 56% Upside Potential in the Biotech Sector

CG Oncology, Inc. (NASDAQ: CGON) is a promising player in the biotechnology sector, with a current market capitalization of $3.32 billion. As a late-stage clinical biopharmaceutical company, CG Oncology focuses..

Schrodinger, Inc. (SDGR) Investor Outlook: Analyzing the 22.84% Potential Upside

Schrodinger, Inc. (NASDAQ: SDGR) has been making waves in the healthcare sector, particularly within the health information services industry. With a robust market capitalization of $1.42 billion, this New York-based..

Tarsus Pharmaceuticals (TARS) Stock Report: Eye-Catching Growth and Promising Analyst Ratings

Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a leading player in the biotechnology sector focusing on eye care, has been grabbing the attention of investors with its impressive market capitalization of $3.08..

LivaNova PLC (LIVN) Stock Analysis: A 20% Upside Potential in the Medical Devices Sector

LivaNova PLC (NASDAQ: LIVN), a prominent player in the medical technology sector, presents a compelling opportunity for investors seeking exposure to the healthcare industry. With a market capitalization of approximately..

Arcellx, Inc. (ACLX) Investor Outlook: Exploring a 30% Upside in Biotech Innovation

Arcellx, Inc. (NASDAQ: ACLX) emerges as an intriguing player in the biotechnology sector, offering investors a compelling narrative driven by its innovative immunotherapy pipeline and a noteworthy potential upside. With..

AtriCure, Inc. (ATRC) Stock Analysis: Unpacking a 33.48% Potential Upside in the Healthcare Sector

AtriCure, Inc. (NASDAQ: ATRC), a leading player in the medical instruments and supplies industry, stands out with its compelling growth narrative and significant investor interest. With a market capitalization of..

Perrigo Company plc (PRGO) Stock Analysis: Analyzing a 54% Potential Upside for Investors

Investors looking for opportunities in the healthcare sector may want to turn their attention to Perrigo Company plc (NYSE: PRGO), a notable player in the specialty and generic drug manufacturing..

Viking Therapeutics, Inc. (VKTX)

⚠️ No article content returned.

..

Scholar Rock Holding Corporation (SRRK): Analyst Consensus Points to a Promising 68% Upside

Scholar Rock Holding Corporation (NASDAQ: SRRK) stands at the forefront of biopharmaceutical innovation, focusing on pioneering treatments for serious diseases influenced by protein growth factor signaling. Headquartered in Cambridge, Massachusetts,..

Ascentage Pharma Group International (AAPG) Investor Outlook: Navigating Growth in Biotech with a 7.62% Upside Potential

Ascentage Pharma Group International (AAPG), a pioneering clinical-stage biotechnology firm based in Suzhou, China, commands attention within the healthcare sector. With a market capitalization of $3.28 billion, the company is..

Veracyte, Inc. (VCYT) Stock Analysis: Exploring the 12% Potential Upside for Investors

Veracyte, Inc. (NASDAQ: VCYT), a leading player in the healthcare sector specializing in diagnostics and research, presents an intriguing opportunity for investors. With its current market capitalization at $2.88 billion..

Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Exploring Growth Potential with a 5.06% Upside

Investors looking for opportunities in the healthcare sector may want to take a closer look at Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN). This Rockville, Maryland-based biopharmaceutical company is making strides in..

Kiniksa Pharmaceuticals (KNSA): Investor Outlook on a 29% Upside Potential in the Biopharma Space

Kiniksa Pharmaceuticals, Ltd. (KNSA) is making waves in the healthcare sector, specifically within the niche of drug manufacturing that focuses on specialty and generic products. With a market capitalization of..

Twist Bioscience Corporation (TWST) Stock Analysis: Exploring a 20% Upside Potential

Twist Bioscience Corporation (NASDAQ: TWST), a leader in the diagnostics and research sector, is capturing investor attention with its innovative approach to synthetic DNA manufacturing. Headquartered in South San Francisco,..

Catalyst Pharmaceuticals (CPRX) Stock Analysis: A Potential 63% Upside in the Biotech Sector

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) stands out in the biotechnology industry with its promising growth potential and a significant upside that could catch the eye of forward-thinking investors. With a..

PROCEPT BioRobotics (PRCT) Stock Analysis: A Healthcare Innovator with 80.59% Potential Upside

PROCEPT BioRobotics Corporation (NASDAQ: PRCT) stands out in the healthcare sector as a promising player, particularly within the medical devices industry. With a focus on innovative surgical robotics, the company..

Belite Bio, Inc (BLTE) Stock Analysis: A Closer Look at the Biotech Firm’s Growth Potential Amidst Promising Clinical Trials

Belite Bio, Inc (NASDAQ: BLTE) is capturing investor attention with its current market performance and promising pipeline of innovative therapeutic solutions. As a clinical-stage biopharmaceutical company, Belite Bio focuses on..

DENTSPLY SIRONA Inc. (XRAY) Stock Analysis: Exploring a 25.95% Potential Upside in the Healthcare Sector

DENTSPLY SIRONA Inc. (XRAY), a prominent player in the healthcare sector, stands out in the medical instruments and supplies industry with its extensive portfolio of dental and healthcare solutions. With..

Concentra Group Holdings (CON): Healthcare Stock with 40% Upside Potential

For investors looking to capitalize on growth within the healthcare sector, Concentra Group Holdings Parent (CON) offers an intriguing opportunity. Positioned at the intersection of medical care facilities and occupational..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds